Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Dashenlin Pharmaceutical (603233.SS)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (Rmb)	Price Target (Rmb)	Rating
2022-02-16	26.42	51.042	Buy
2022-05-05	20.00	27.75	Buy
2022-11-02	31.55	41.667	Buy
2023-04-11	31.49	43.333	Buy
2023-04-29	28.68	41.25	Buy
2023-08-30	26.82	38.50	Buy
2023-10-31	23.80	35.50	Buy
2024-04-29	21.60	32.00	Buy
2024-10-08	16.98	20.70	Buy
2024-10-31	14.49	20.20	Buy
2025-04-28	17.76	22.10	Buy

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.